TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05512221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GBAT+I, GBAT+E - Phase I
Description: Phase I is the development phase, which is informed by the study team's previous pilot study and autistic advisors. It will include the development of engagement booster materials. Booster materials will be tested in 2 groups (GBAT+I and GBAT+E) of six participants each. Groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions) and GBAT+Engagement Booster (GBAT+E; supplemental materials). The first 4-6 eligible adults recruited will participate in GBAT+I and the second 6 eligible adults recruited will participate in GBAT+E. Both groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watchful Waiting and Groups - Phase 2
Description: Phase 2a will include a watchful waiting (WW) condition and assignment to 1 of 2 treatment conditions: GBAT+I or GBAT+E.~Participants will be assigned to WW for 10 wks. They will not receive specific therapeutic services during WW, but a member of the study team will contact them at weeks 1, 2, 4, 6, and 8 to maintain engagement and monitor for clinical deterioration.~After WW, participants will be randomly assigned to one of the treatment conditions (GBAT+I or GBAT+E). All groups will consist of 10 weekly 60-90-minute GBAT group sessions. GBAT+I participants will attend four 30-minute individual booster sessions. GBAT+E participants will be asked to use booster materials between group sessions (e.g., worksheets, goal trackers, interactive learning activities)~WW group size is based on study feasibility and availability of resources. Additional participants will also be recruited at the end of the WW period to supplement group sizes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GBAT+IE
Description: Phase 2b will include assignment to GBAT+IE, which includes components of both GBAT+I (individual sessions) and GBAT+E (supplemental materials)~All groups will consist of 10 weekly 60-90-minute GBAT group sessions. Participants in the GBAT+I group will also attend 30-minute individual booster sessions, approximately between Weeks 4-5, 5-6, 6-7, and 7-8. Participants in the GBAT+E group will be asked to use booster materials in between group sessions (e.g., worksheets, goal trackers, interactive learning activities). Participants in GBAT+IE will participate in both the individual sessions and use of booster materials.
Study: NCT06259565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (Dex) is an α2-adrenergic agonist sedative commonly used in IMV that promotes patient wakefulness, has no effect on respiratory drive, has important analgesic properties, and reduces delirium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Those in the control group will receive a placebo that is identical in colour and packaging and at equal volume to the intervention group. Each bag of placebo contains 100mL of 0.9% sodium chloride and labeled as per Health Canada guidance for labelling pharmaceutical drugs for use in humans
Study: NCT05953077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversational recasting
Description: The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conversational recasting
Description: The treatment procedure uses 24 treatment doses embedded into child-friendly activities (crafts, book reading, play). Each each consists of a clinician eliciting use of a targeted grammatical form, a child's attempt (correct or incorrect) to use that form, and an immediate clinician repetition of the child's attempt (a recast), correcting any ungrammatical elements as needed. Clinicians must also attempt to gain the child's attention before providing the recast. Treatment sessions are approximately 30 minutes in duration.
Study: NCT05390502

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: manual monitoring and general education on use
Description: Patients will receive a standard blood pressure monitor and education on how to use it. Data will be reported as part of usual care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated monitoring and local wrap-around hypertension program
Description: Patients will receive a standard blood pressure monitor and a local wrap-around hypertension program. Data will be sent directly to their participating health system.
Study: NCT05714527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Close-loop FiO2 controller
Description: Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.
Study: NCT06109948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX1100 injection for IV infusion
Description: Centyrin protein-siRNA conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX1100 injection for IV infusion
Description: Centyrin protein-siRNA conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX1100 injection for IV infusion
Description: Centyrin protein-siRNA conjugate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection for IV infusion
Description: placebo saline injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection for IV infusion
Description: placebo saline injection
Study: NCT05424471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN)
Description: The FSN intervention lesson is taught to participants previously randomized into the FSN intervention group during the PECO 1 study. Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the 1 - 45 minute lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group - Vehicle Safety
Description: The control (vehicle safety) lesson is taught to participants previously randomized into the control group during the PECO 1 study. Control group participants receive 1 - 30 minute lesson with vehicle safety information, taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
Study: NCT05544461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eNutri personalised nutrition advice
Description: eNutri is a web-based app that administers an FFQ and delivers PN advice to the user. The advice is generated from their responses in the FFQ and considers their sex and dietary restrictions (such as whether they eat meat) so the reports are unique to each participant. This report (referred to as a 'healthy eating report') will also include an interactive component, allowing the participant to reflect on the advice received and set personal healthy eating goals to motivate behaviour change. The messages presented in the report have been developed by the eNutri Team, including a registered dietitian and registered nutritionist and are in line with UK dietary guidelines (primarily the EatWell Guide).
Study: NCT04917575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Game
Description: An enhanced life-simulation prototype of a playable interactive game to increase HIV testing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Application
Description: A mobile application that will include basic information on HIV basics (e.g., routes of transmission, data on the epidemiology of HIV among youth), prevention information, and information on HIV testing and PrEP, as well as a link to the HIV risk estimator, and HIV testing and PrEP locators.
Study: NCT05933434

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogenic adipose derived mesenchymal stem cells (AD-MSC)
Description: Laboratory isolated, cultivated and cryopreserved allogenic adipose derived mesenchymal stem cells (AD-MSC) from health donors undergoing cometic plastic surgery will be thawed on the injection day and formulated in 10 mL saline. The AD-MSCs will then be intraarticular injected using ultrasonic guidance.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10 mL saline will be intraarticular injected using ultrasonic guidance.
Study: NCT05875038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video system
Description: The video surveillance system will analyze the position of subjects in real time using algorithms based on artificial intelligence. The system works continuously without video capture and sends an alert with a photo if a person is lying down after a fall. The alert is confirmed after an operator has checked the photo capture on a dedicated platform.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-alarm
Description: Tele-alarm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tele-alarm
Description: Tele-alarm
Study: NCT05131893

Intervention type: DRUG
Intervention: Docetaxel
Description: chemotherapy

Intervention type: DRUG
Intervention: Docetaxel
Description: chemotherapy
Study: NCT05892458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: To perform abdominal massage, patients should keep their upper body in an upright or semi-decumbent position. Using their right four fingers or palm, they should apply pressure to the middle point of the lower margin of the right upper abdominal ribs, which corresponds to the opening of the gallbladder and common bile duct. The pressure should be firm, with a depth of approximately 3-4 cm and a length of 5-10 cm, and should be applied at least once a day for 10-15 minutes per session.
Study: NCT05520671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified online quizzing platform
Description: TESLA-G is a novel gamified quizzing platform designed based on Bloom's taxonomy of learning domains. Questions will be created in blocks, where each block will test a specific topic within a specialty (endocrine surgery has been selected for this study). Each block has 5 questions, and each question corresponds to each level of Bloom's taxonomy and each level in game.~For this study, we aim to create 56 blocks of 5 questions, totalling 280 questions. All questions will be created by two board-certified general surgeons and one endocrinologist, and validated by the research team.~The aim of the game is for players to get as many points as they can before the timer runs out. Gamification elements include levels, countdown timer, lives, a point multiplier system, leaderboard rankings and a personalised dashboard.~Participants in the intervention group will be provided with a link to access TESLA-G, sent from an automated Telegram bot; this access will be provided for 14 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional quizzing platform
Description: The conventional quizzing platform will be a modified version of TESLA-G with all gamification elements removed. The same set of questions as the gamified version will be used. Upon entering the quiz, a question stem and five choices will be shown. When an option is selected, the right answer along with its explanation will be indicated. The next question will then be sent, and this process repeats until the participant leaves the platform or has answered every question.~Questions will be queued in blocks, with each block corresponding to a particular topic in endocrine surgery. Unlike the gamified version, questions within each block will be randomised, regardless of their level on the Bloom's taxonomy. Participants will also not be informed of the level of Bloom's taxonomy for individual questions. The access link to the platform will be sent to participants from an automated Telegram bot, and this access will last for 14 days.
Study: NCT05131893

Intervention type: DRUG
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Intervention: paclitaxel
Description: chemotherapy

Intervention type: DRUG
Intervention: trastuzumab
Description: biological treatment

Intervention type: DRUG
Intervention: trastuzumab
Description: biological treatment

Intervention type: DRUG
Intervention: pertuzumab
Description: biological treatment

Intervention type: DRUG
Intervention: Capecitabine
Description: chemotherapy
Study: NCT05838729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiMO-301
Description: A single dose of RiMO-301 will be administered via an intratumoral injection.~PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity.~Patients will receive hypofractionated radiation in 5 fractions.
Study: NCT05524324

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT ON (biventricular pacing) / CRT OFF (inactive or univentricular pacing)
Description: Patients randomized to the CRT ON / CRT OFF arm will undergo a first intervention to activate their device and then a second intervention for 3 months to inactivate their device.

Intervention type: DEVICE
Group type: OTHER
Intervention: CRT OFF (inactive or univentricular pacing) / CRT ON (biventricular pacing)
Description: Patients randomized to the CRT OFF / CRT ON arm will undergo a first intervention to inactivate their device and then a second intervention for 3 months to activate their device.
Study: NCT06297824

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ERGT-A
Description: Emotion regulation group therapy for adolescents
Study: NCT06573671

Intervention type: DIAGNOSTIC_TEST
Intervention: Chitotriosidase
Description: The amount of patients with increased chitotriosidase, and the extent of elevation of chitotriosidase

Intervention type: DIAGNOSTIC_TEST
Intervention: Mass spectrometry
Description: to show PVP presence in histiocytes of injecting drug users compared to controls

Intervention type: DIAGNOSTIC_TEST
Intervention: X-ray spectromicroscopy
Description: to show PVP presence in histiocytes of injecting drug users compared to controls

Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescence microscopy
Description: to show PVP presence in histiocytes of injecting drug users compared to controls

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptomics
Description: To describe pathologic signals of PVP-exposed in vitro histiocytes of injecting drug users compared to control samples
Study: NCT06237426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: A course of methylone treatment includes weekly oral methylone administrations for up to 4 weeks.~Participants may be eligible to receive up to two courses of methylone treatment in this study. After a course of methylone treatment is complete, participants will return to observational study visits.
Study: NCT05660616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The study includes patients with unresectable malignant pleural mesothelioma who received at least 4 cycles of first line platinum (Cisplatin or Carboplatin) and pemetrexed combination chemotherapy~* Response after first line treatment will be assessed by the modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1 for pleural mesothelioma.~* Patients will be randomized according to a (1:1) ratio to either Arm 1: Administration of maintenance gemcitabine (1000 mg/m²) on days 1 and day 8, in cycles of 21 days plus supportive care Arm 2 (control arm): best supportive care alone.~* Cases will be evaluated every cycle clinically and every three cycles radiologically with CTs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supportive care
Description: supportive care

Intervention type: OTHER
Group type: OTHER
Intervention: supportive care
Description: supportive care
Study: NCT06000839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (D0) Intradermal injection - micropapula technique
Description: First injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (D14) Intradermal injection - micropapula technique
Description: Second injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (D28) Intradermal injection - micropapula technique
Description: Third injection of the product (3ml) in the medium and lower third of the face (whole face excepted forehead)
Study: NCT05949476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone therapy
Description: Ozone in the gaseous state produced by a machine at concentrations for medical use (sssssssssss9) injected after anesthesia in the surgery site and in the post-extraction alveolus after suture.~* Topical ozone in the form of a gel (indicate the brand) to be applied to the post-surgical site 2 times a day for 7 days.
Study: NCT06364124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evolocumab
Description: Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard post-treatment for STEMI
Description: standard post-treatment for STEMI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard post-treatment for STEMI
Description: standard post-treatment for STEMI
Study: NCT06236958

Intervention type: DEVICE
Intervention: Transnasal jejunal tube
Description: A naso-jejunal tube was placed in the operation, which is placed 15 cm below Traitz's ligament. A short-peptide enteral nutrient solution was heated by an enteral nutrient pump and infused into the patients within 24 hours after the operation. Before and at the end of the infusion, physiological saline was given to flush the tube, and at the end of the infusion, the catheter was closed to prevent liquid reflux and blockage of the tube. The catheter should be clamped shut at the end of the infusion. During the infusion period, the patient's gastrointestinal tolerance was dynamically evaluated. According to the results of a regular review of nutritional indicators, including hemoglobin, albumin, electrolytes, liver and kidney function, etc., increase the amount of enteral nutrients; remove the nasojejunal tube when the patient has no abdominal distension after exhaustion and feeding; and change to feeding through the mouth.

Intervention type: OTHER
Intervention: Transvenous access
Description: A uniform drip of nutritional solution was started 24 hours postoperatively. Configuration of nutritional solution: glucose and medium/long-chain fat emulsion as the main energy substances to provide calories, calculated at 30 \~ 35 kcal/(kg-d), glucose-fat ratio is 6:4, pancreatic glucose ratio for those without a history of diabetes mellitus is 1:6 \~ 8, and for diabetic patients depending on the level of glucose, pancreatic glucose ratio is 1:3 \~ 4, and then assisted with subcutaneous injections of insulin to control glucose, if necessary. Pay attention to the total amount of rehydration fluid, electrolytes, vitamins, and trace elements supplemented. Mix the nutrient solution evenly in the laminar flow clean table and infuse it through the route at 2500\~3000 ml/d; the infusion time is 8\~12 h/d. After exhaustion, start to eat through the mouth.
Study: NCT05627895

Intervention type: OTHER
Intervention: Neurofeedback
Description: Participants will be shown their brain activity measured in real-time using an MRI scanner. They can then use mental strategies, such as imagination to influence and regulate this activity.
Study: NCT06361511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Linoleic Acid Foods
Description: Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Acid Foods
Description: Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily
Study: NCT05040711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach
Description: This study will use Mindfulness Coach, an iOS- and Android-based app designed to deliver a mindfulness training course centered on Veteran's Affairs (VA) protocols. Developed by the VA's National Center for PTSD, the app provides an engaging introduction to MT, regardless of specific psychiatric illness or patient population. The app provides a training plan with 14 sequential levels, a practice now area with evidence-based mindfulness audio exercises, assessments using the Five-Factor Mindfulness Questionnaire Short Form (FFMQ-SF)90, and education about mindfulness. To progress to the next level, the user must interact with every element. The training plan levels include psychoeducation and exercises (guided meditations and seated practices), which increase in duration as users progress. Levels 1,7 and 14 also include an assessment with the FFMQ-SF. The practice now area has guided meditations to practice new skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: A a widely available health and wellness app that provides users with daily content on general health, WebMD, will serve as the attention control. Similar health-based apps have been used as controls in other mHealth psychotherapy intervention trials.100,101 The control group will be instructed to access the app 4x/week (same as intervention group) and will receive an orientation and 2 booster sessions as well. I considered other control group options including treatment as usual, but attention control was selected due to the variability of treatment as usual.